An experienced accounting and finance executive, Peter Culpepper is the chief financial officer and chief operating officer of Provectus Biopharmaceuticals. Earlier this year, Peter Culpepper’s company announced that it would start a phase 1 study of the efficacy of PV-10 in the treatment of neuroendocrine tumors that have metastasized in the liver. The trial will involve 12 patients and will take place at the Queen Elizabeth Hospital in South Australia.
With the phase 1 study, the researchers hope to test the safety and tolerability, as well as the effectiveness, of PV-10 chemoablation. The study will run for two years, with interim data taken after a year. Participants are divided into two successive cohorts. The first will receive PV-10 treatment in a single liver tumor, while the second will receive treatment in multiple tumors.
To judge effectiveness of the treatment, research will assess the objective response rate of both treated and untreated tumors, as well as any changes in tumor biomarkers that might occur. The key biomarkers include 5-hydroxyindole acetic acid, chromogranin A, and somatostatin receptor expression.